Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 2Macular Edema 2von Hippel-Lindau Disease 1Retinal Diseases 1Neoplasms 1Melanoma 1Glaucoma, Neovascular 1Conjunctival Neoplasms 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Specimen Handling 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Ranibizumab × Clear all
NCT00750399 2012-04-26

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

The New York Eye Cancer Center

Phase 1 Completed
10 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Retinal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡